Live tape
Top 8, mentions 7d10,583TSLA2,459 mentions▲ +0.06SPCX1,979 mentions▲ +0.08GOOGL1,315 mentions▲ +0.04CRWV1,189 mentions▲ +0.04NVDA1,056 mentions▲ +0.07QQQ1,022 mentions▲ +0.05META795 mentions▲ +0.05NBIS768 mentions▲ +0.07

Equity · Healthcare

CRNX

NASDAQ

Crinetics Pharmaceuticals (CRNX)

$85 +0.18% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Aug 31, 2026
Price · Chart
15 sessions
$85.5 $83.5 23 Jul 31 Aug

The line runs $83.66 on 23 July through $85 on 31 August, on a scale from $83.5 to $85.5. Days the market did not trade hold the previous close, flat.

Market cap $9.0B
52-week range $30 – $85
Avg volume 1.0M

as of Aug 31, 2026

Crinetics Pharmaceuticals (CRNX) insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 1 Sep 2026

In the 90 days to 21 Oct 2026, no Crinetics Pharmaceuticals insider bought or sold shares on the open market; all 13 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Open-market buys 0
Open-market sells 0
Non-trade filings 13

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Sep 2026 Bedrosian Camille L Director Other 22,225 $1.89M
01 Sep 2026 Betz Stephen F. Chief Scientific Officer Other 137,936 $11.72M
01 Sep 2026 Struthers Richard Scott President & CEO Other 1,402,911 $119.25M
01 Sep 2026 Schilke Tobin Chief Financial & Infra. Ofcr. Other 79,427 $6.75M
01 Sep 2026 Kalofonos Isabel Chief Commercial Officer Other 35,669 $3.03M
01 Sep 2026 Deardorf Caren Director Other 22,225 $1.89M
01 Sep 2026 Fust Matthew K Director Other 28,761 $2.44M
01 Sep 2026 Nichols Weston Director Other 22,225 $1.89M
01 Sep 2026 Okey Stephanie Director Other 12,325 $1.05M
01 Sep 2026 Vivaldi Coelho Rogerio Director Other 19,225 $1.63M
01 Sep 2026 WIERENGA WENDELL Director Other 122,071 $10.38M
20 Aug 2026 Schilke Tobin Chief Financial & Infra. Ofcr. Award 471

Showing the 12 most recent of 13 compensation filings in this window. The figures above count all of them.

Crinetics Pharmaceuticals (CRNX) reported financials

SEC EDGAR XBRL SEC EDGAR

Crinetics Pharmaceuticals reported revenue of $7.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$465.3M.

Figure Reported Period
Revenue $7.7M 31 Dec 2025 fiscal year
Net income −$465.3M 31 Dec 2025 fiscal year
Diluted EPS −$4.95 31 Dec 2025 fiscal year
Total assets $1.3B 30 Jun 2026 at period end
Total equity $1.2B 30 Jun 2026 at period end

Crinetics Pharmaceuticals (CRNX) earnings

SEC EDGAR

Crinetics Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.14; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.14 —
31 Mar 2026 Q1 2026 −$1.23 —
31 Dec 2025 FY 2025 −$4.95 —
30 Sep 2025 Q3 2025 −$1.38 —
30 Jun 2025 Q2 2025 −$1.23 $1M
31 Mar 2025 Q1 2025 −$1.04 $0M
31 Dec 2024 FY 2024 −$3.69 $1M
30 Sep 2024 Q3 2024 −$0.96 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Crinetics Pharmaceuticals (CRNX) institutional holders (13F)

SEC Form 13F SEC EDGAR

7 of the 45 institutional funds we track reported a Crinetics Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $170.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 2,351,465 $88.0M
Marshall Wace Added +64.7% shares 1,126,639 $42.2M
Fisher Asset Management Held (±25%) −2.8% shares 741,553 $27.7M
Citadel Advisors Trimmed −56.5% shares 138,329 $5.2M
Two Sigma Investments Held (±25%) 87,299 $3.3M
Man Group Added +28.3% shares 61,043 $2.3M
Point72 Asset Management New position 46,381 $1.7M

Congressional trades in Crinetics Pharmaceuticals (CRNX)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Crinetics Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 03 Mar 2026.

Date Member Type Amount
03 Mar 2026 filed 07 Apr 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
17 Apr 2025 filed 06 May 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
19 Mar 2025 filed 10 Apr 2025 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
29 Jan 2025 filed 11 Feb 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
25 Sep 2024 filed 03 Oct 2024 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K

Crinetics Pharmaceuticals (CRNX): frequently asked questions

From live data

Have Crinetics Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, no Crinetics Pharmaceuticals insider bought or sold shares on the open market; all 13 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

How many institutions hold Crinetics Pharmaceuticals?

7 of the 45 institutional funds we track reported a Crinetics Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

When did Crinetics Pharmaceuticals last report earnings?

Crinetics Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.14; no next date is announced in SEC filings yet.

What exchange is Crinetics Pharmaceuticals listed on?

Crinetics Pharmaceuticals trades on NASDAQ under the ticker CRNX.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SEC EDGARValuation computed from SEC EDGAR filings